VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Part of paid clinical trials in Anaheim, California.
- Sponsor
- GlaxoSmithKline
- Study ID
- NCT00306293
- Phase
- PHASE4
- Status
- Completed
Conditions
- Herpes Labialis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- valacyclovir — DRUGvalacyclovir
Study Details
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
Key Dates
- Start date
- Feb 20, 2006
- Status verified
- Aug 2017
- Primary completion
- Nov 27, 2006
- Completion
- Nov 27, 2006
Study Design
- Enrollment
- 70 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Primary Outcome Measure
Mean Percent Days of Total Shedding (Clinical and Subclinical) as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for Herpes Simplex Virus Type 2 (HSV-2) [ Time Frame: Up to 60 days in each treatment period (Up to 148 days) ]
Locations (18)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| GSK Investigational Site | Anaheim | California | 92805 | - |
| GSK Investigational Site | Carmichael | California | 95608 | - |
| GSK Investigational Site | Fair Oaks | California | 95628 | - |
| GSK Investigational Site | Sacramento | California | 95816 | - |
| GSK Investigational Site | San Diego | California | 92123 | - |
| GSK Investigational Site | Boynton Beach | Florida | 33437 | - |
| GSK Investigational Site | St. Petersburg | Florida | 33710 | - |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | - |
| GSK Investigational Site | South Bend | Indiana | 46601 | - |
| GSK Investigational Site | Portage | Michigan | 49024 | - |
| GSK Investigational Site | New York | New York | 10029 | - |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | - |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | - |
| GSK Investigational Site | Tulsa | Oklahoma | 74104 | - |
| GSK Investigational Site | Portland | Oregon | 97210 | - |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | - |
| GSK Investigational Site | Memphis | Tennessee | 38104 | - |
| GSK Investigational Site | Memphis | Tennessee | 38120 | - |
Find similar trials in Anaheim, CA
Related Studies
- Viral Infections in Healthy and Immunocompromised HostsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland